Open Label, Phase II Study Investigating the Efficacy of Posaconazole as Prophylaxis Antifungal Agent in Aplastic Anemia / Hypoplastic Myelodysplastic Syndrome Patients Undergoing Antithymocyte Globulin Treatment
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2018
At a glance
- Drugs Posaconazole (Primary)
- Indications Mycoses
- Focus Therapeutic Use
- 22 Apr 2018 Planned End Date changed from 31 Dec 2019 to 30 Jun 2020.
- 22 Apr 2018 Status changed from not yet recruiting to recruiting.
- 27 Oct 2017 New trial record